IL-5, IL-6, IL-13, IL-17, IL-23, and TNF-α are targetable with biologics developed for spontaneous autoimmunity, and our data broadly support the prospective investigation of these inhibitors for patients with irAEs (21–23, 26, 27, 62). The gene discussed is IL17A; the disease is Autoimmunity.